Back to top

biotechs: Archive

Zacks Equity Research

Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?

Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.

JNJPositive Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change

Zacks Equity Research

Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe

Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.

NVSPositive Net Change PFENegative Net Change BPMCNegative Net Change DCPHPositive Net Change

Zacks Equity Research

Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline

Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.

BIIBNegative Net Change RHHBYPositive Net Change BMYPositive Net Change PRTANegative Net Change

Zacks Equity Research

Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

BMYPositive Net Change PFENegative Net Change MRKNo Net Change CLVSNegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

BEAMNegative Net Change SRPTPositive Net Change EDITNegative Net Change CRSPNegative Net Change

Zacks Equity Research

Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

RHHBYPositive Net Change SGENPositive Net Change TAKNegative Net Change GMABPositive Net Change

Zacks Equity Research

Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx

The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.

RHHBYPositive Net Change BMYPositive Net Change BAYRYPositive Net Change EXELNegative Net Change

Indrajit Bandyopadhyay

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.

BEAMNegative Net Change SRPTPositive Net Change EDITNegative Net Change CRSPNegative Net Change

Zacks Equity Research

Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe

While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.

RHHBYPositive Net Change BMYPositive Net Change PFENegative Net Change EPZMNegative Net Change

Zacks Equity Research

Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease

Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.

BEAMNegative Net Change EDITNegative Net Change NTLANegative Net Change CRSPNegative Net Change

Zacks Equity Research

Novavax (NVAX) Concentrates on COVID-19 Vaccine Development

While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.

AZNPositive Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change

Zacks Equity Research

Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?

Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.

SNYPositive Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

Incyte's (INCY) Going Gets Rough Despite Recent Approvals

Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

BMYPositive Net Change PFENegative Net Change INCYNegative Net Change ABBVPositive Net Change

Benjamin Rains

Find 'Strong Buy' Stocks for October and Beyond with this Screener

Given this backdrop, investors with long-term horizons should remain on the hunt for stocks because timing the market is difficult. Utilizing our Filtered Zacks Rank 5 Stock Screener is a great place to start...

JPMPositive Net Change ALKSNegative Net Change SBPositive Net Change

Zacks Equity Research

Markets Await Economic and Earnings Data

Markets Await Economic and Earnings Data

JPMPositive Net Change NKEPositive Net Change PFENegative Net Change DALNegative Net Change COSTPositive Net Change MRNANegative Net Change FDXPositive Net Change

Indrajit Bandyopadhyay

3 Small Biotech Stocks in Focus on World Arthritis Day

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

JNJPositive Net Change AMGNPositive Net Change ABBVPositive Net Change ALPNNegative Net Change IMABNegative Net Change BVSNegative Net Change

Zacks Equity Research

bluebird (BLUE) Gives Details on Oncology Business Spinoff

bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.

REGNNegative Net Change NVSPositive Net Change BMYPositive Net Change BLUEPositive Net Change

Zacks Equity Research

Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status

Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.

BIIBNegative Net Change RHHBYPositive Net Change LLYPositive Net Change PRTANegative Net Change SAVANegative Net Change

Zacks Equity Research

4 Reasons to Add Regeneron (REGN) Stock to Your Portfolio

Regeneron (REGN) is expected to gain from a solid and diverse portfolio despite stiff competition for its key drugs. The promising pipeline also sets the stage for growth further.

REGNNegative Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease

Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.

REGNNegative Net Change VRTXNegative Net Change HZNPNegative Net Change FBIONo Net Change

Madeleine Johnson

Why CRISPR Therapeutics (CRSP) Stock is Falling Today

Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?

CRSPNegative Net Change

Zacks Equity Research

Amgen (AMGN) Reports New Data From Lumakras Combo Study

Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.

REGNNegative Net Change AMGNPositive Net Change VRTXNegative Net Change HZNPNegative Net Change

Zacks Equity Research

Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies

The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.

BMYPositive Net Change BLUEPositive Net Change ALLONegative Net Change SWTXNegative Net Change

Zacks Equity Research

Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada

Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.

RARENegative Net Change VTVTNegative Net Change EVLONegative Net Change GRTSNegative Net Change

Zacks Equity Research

Bristol Myers (BMY) UC Candidate Fails in Phase II Study

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.

RHHBYPositive Net Change BMYPositive Net Change MRKNo Net Change AMGNPositive Net Change